Therapeutic potential of TNFα inhibitors in chronic inflammatory disorders: Past and future

Hongtao Zhang; Nelson Shi; Zhuo Diao; Youhai Chen; Yejia Zhang

doi:10.1016/j.gendis.2020.02.004

您当前的位置：

首页 >

文章列表页 >

Therapeutic potential of TNFα inhibitors in chronic inflammatory disorders: Past and future

更新时间：2022-06-24

- Therapeutic potential of TNFα inhibitors in chronic inflammatory disorders: Past and future
- Genes & Diseases Vol. 8, Issue 1, (2021)
- 作者机构：
  
  1. Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia,PA,USA
  2. Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia,PA,USA
  3. Department of Physical Medicine & Rehabilitation, Perelman School of Medicine, University of Pennsylvania, Philadelphia,PA,USA
  4. Translational Musculoskeletal Research Center (TMRC), Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia,PA,USA
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2020.02.004
  CLC：
- Published：2021，
  
  Published Online：1 January 2021，
扫描看全文
Hongtao Zhang, Nelson Shi, Zhuo Diao, et al. Therapeutic potential of TNFα inhibitors in chronic inflammatory disorders: Past and future. [J]. Genes & Diseases 8(1).(2021)
DOI：

Hongtao Zhang, Nelson Shi, Zhuo Diao, et al. Therapeutic potential of TNFα inhibitors in chronic inflammatory disorders: Past and future. [J]. Genes & Diseases 8(1).(2021) DOI： 10.1016/j.gendis.2020.02.004.

摘要

Abstract

In the past 20 years

patients with rheumatoid arthritis (RA)

Crohn's disease (CD)

and other immune diseases have witnessed the impact of a great treatment advance with the availability of biological TNFα inhibitors. With 5 approved anti-TNFα biologics on the market and soon available biosimilars

patients have more treatment options and have benefited from understanding the biology of TNFα. Nevertheless

many unmet needs remain for people living with TNFα-related diseases

namely some side effects and tolerance of current anti-TNFα biologics and resistance to therapies. Furthermore

common diseases such as osteoarthritis and back/neck pain may respond to anti-TNFα therapies at early onset of symptoms. Development of new TNFα inhibitors focusing on TNFR1 specific inhibitors

preferably small molecules that can be delivered orally

is much needed.

关键词

Keywords

AntibodiesReceptorsSmall molecule inhibitorsTNFαTNFR1

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Lysyl oxidase inhibition enhances browning of white adipose tissue and adaptive thermogenesis

Immune characteristics analysis reveals two key inflammatory factors correlated to the expressions of SARS-CoV-2 S1-specific antibodies

A peptide-based assay discriminates individual antibody response to SARS-CoV-2

Related Author

Haiyan Huang

Qiqun Tang

Yang Liu

Duo Jiang

Chun Xing

Xiaojian Han

Aishun Jin

Jianwei Wang

Related Institution

Key Laboratory of Metabolism and Molecular Medicine, The Ministry of Education, Department of Biochemistry and Molecular Biology, Fudan University School of Basic Medical Sciences

Department of Immunology, College of Basic Medicine, Chongqing Medical University

Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University

Department of Breast Surgery, Harbin Medical University Cancer Hospital

Dipartimento di Scienze e Tecnologie, Università degli Studi del Sannio, Via dei Mulini snc

⁰